Stephens Lowers Immunome (NASDAQ:IMNM) Price Target to $30.00

Immunome (NASDAQ:IMNM) had its price objective dropped by equities researchers at Stephens from $33.00 to $30.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ price target suggests a potential upside of 43.20% from the company’s previous close.

A number of other research analysts also recently commented on IMNM. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Evercore upped their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. HC Wainwright began coverage on shares of Immunome in a report on Thursday, February 12th. They issued a “buy” rating and a $40.00 price objective on the stock. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Truist Financial assumed coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Immunome Stock Down 7.0%

Shares of NASDAQ:IMNM opened at $20.95 on Wednesday. The company has a market cap of $2.31 billion, a PE ratio of -8.66 and a beta of 2.12. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $27.65. The firm has a 50-day simple moving average of $22.75 and a 200 day simple moving average of $17.60.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Philip Tsai bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the transaction, the insider directly owned 43,300 shares of the company’s stock, valued at approximately $887,217. This represents a 30.03% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Clay B. Siegall purchased 4,729 shares of the company’s stock in a transaction on Tuesday, December 30th. The shares were bought at an average price of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the transaction, the chief executive officer directly owned 665,254 shares in the company, valued at $14,070,122.10. This represents a 0.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 68,518 shares of company stock valued at $1,453,958 over the last 90 days. 7.69% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunome

Institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its position in shares of Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the period. Invesco Ltd. boosted its stake in Immunome by 382.1% during the fourth quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock valued at $5,801,000 after buying an additional 214,049 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in Immunome by 16.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after acquiring an additional 1,970 shares during the period. Wellington Management Group LLP raised its position in Immunome by 267.8% in the fourth quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock worth $20,072,000 after acquiring an additional 680,395 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new stake in Immunome in the 4th quarter valued at about $2,741,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.